ArticleNeuro-oncology practice2025
Risk of central nervous system metastasis and survival in HER2+ positive breast and non-breast cancers.
Article in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Incidence, survival, and optimal choice of therapy for central nervous system (CNS) metastasis are well characterized in human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), yet remain poorly defined in other HER2+ solid tumors (STs). Methods: A retrospective cohort analysis was performed to characterize the incidence of CNS metastasis and clinical outcomes in patients with HER2+ breast cancer and ST treated at the University of Virginia Emily Couric Cancer Center between January 2010 and January 2022. Results: In the cohort, 50 patients had HER2+ ST and 383 had HER2+ BC. Of the ST group, 48.0% received CNS imaging at diagnosis as compared to 2.9% of breast cancer patients ( Conclusions: Patients with non-breast cancer HER2+ STs had higher risk of CNS metastasis and poorer OS compared to HER2+ breast cancer patients, with lower utilization of HER2-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.